Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Promoter Share Pledge
Premier Fiscal Services Pvt. Ltd. (promoter) pledged 2,500,000 equity shares of Gennex Laboratories Ltd (Script 531739) to Vidya Tradecon Pvt. Ltd. on June 9, 2026 (DP IN304326 ClientID 10001339); pledge expiry Dec 7, 2026.
Promoter Pledge
Premier Fiscal Services Pvt. Ltd. pledged 2,500,000 equity shares of Gennex Laboratories Ltd to M/s. Vidya Tradecon Pvt. Ltd. (DP: BMD Securities IN304326, Client ID: 10001339) reported on June 09, 2026; expiry Dec 07, 2026.
Share pledge
Premier Fiscal Services Pvt. Ltd. informed BSE (June 9, 2026) that it created a pledge of 2,500,000 equity shares of Gennex Laboratories in favour of M/s Vidya Tradecon Pvt. Ltd. (via BMD Securities, DP ID IN304326, Client ID 10001339), expiring Dec 7, 2026.
Promoter Pledge
Premier Fiscal Services (promoter) pledged 2,500,000 equity shares of Gennex Laboratories (BSE:531739, GENNEX) to Vidya Tradecon Pvt. Ltd. on June 9, 2026 (disclosed June 10); pledge via BMD Securities (IN304326:10001339) expires Dec 7, 2026.
Gennex Laboratories Ltd (GENNEX) is currently trading at 10.59 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gennex Laboratories Limited specializes in manufacturing and exports active pharmaceutical ingredients (APIs) and intermediates, focusing on expectorants, muscle relaxants, analgesics, and antifungal products. The company maintains a global footprint with exports to countries including Germany, UK, Spain, Singapore, Canada, and more, marking its prominence in international markets. It has a vertically integrated business model, enhancing operational efficiencies and product diversification. In 2023, Gennex acquired a 51% share in Deccan Remedies Limited, indicating a strategic move to expand its business scope. The company emphasizes compliance with GMP standards and CGMP guidelines, showcasing its commitment to quality and industry best practices.
Over the past 52 weeks, Gennex Laboratories Ltd has traded between a low of ₹7.05 and a high of ₹17.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gennex Laboratories Ltd has a market capitalization of approximately 257.28. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gennex Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 13.83 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 257.28 Cr, Gennex Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gennex Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gennex Laboratories Ltd is 13.83. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
4
Neutral
6
Bullish
4
Bearish
25
Neutral
6
Bullish
15
Bearish
21
Neutral
0
Bullish
11
Discovery themes featuring this stock
Gennex Laboratories Limited specializes in manufacturing and exports active pharmaceutical ingredients (APIs) and intermediates, focusing on expectorants, muscle relaxants, analgesics, and antifungal products.
The company maintains a global footprint with exports to countries including Germany, UK, Spain, Singapore, Canada, and more, marking its prominence in international markets.
It has a vertically integrated business model, enhancing operational efficiencies and product diversification.
In 2023, Gennex acquired a 51% share in Deccan Remedies Limited, indicating a strategic move to expand its business scope.
The company emphasizes compliance with GMP standards and CGMP guidelines, showcasing its commitment to quality and industry best practices.
Pharmaceuticals & Biotechnology
Pharmaceuticals
257 Cr
High Risk
13.8
34.3
0.3
1.2
17.25
7.05
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
44.00 | 269 Cr | -251.42 | 2.83 | 0.00 | -1.13 | 4.36 | -0.96 | ||
10.59 | 257 Cr | 13.83 | 1.16 | 0.00 | 8.29 | 9.09 | 6.02 | ||
243.70 | 256 Cr | 56.67 | 4.48 | 0.00 | 7.90 | 8.87 | 3.09 | ||
32.40 | 248 Cr | 13.95 | 1.57 | 0.00 | 11.24 | 10.51 | 6.33 | ||
258.90 | 248 Cr | 44.52 | 3.28 | 0.00 | 7.35 | 11.62 | 2.32 | ||
69.50 | 247 Cr | -24.65 | 2.68 | 0.00 | -10.86 | -6.04 | -5.98 | ||
408.40 | 232 Cr | 21.46 | 3.07 | 1.24 | 14.04 | 19.30 | 10.92 | ||
| Median: 7 Co. | — | 69.50 | 248 Cr | 13.95 | 2.83 | 0.00 | 7.90 | 9.09 | 3.09 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
